Carbocisteine promethazine - oral

Concise Prescribing Info
Respiratory tract infections associated with excessive and/or viscous mucus.
Dosage/Direction for Use
Adult : PO Each bottle contains carbocisteine (mg)/promethazine hydrochloride (mg): 100/2.5: 15 mL tid.
Dosage Details
Respiratory tract infections associated with excessive and/or viscous mucus
Adult: Available preparation:
Each bottle contains carbocisteine 100 mg and promethazine hydrochloride 2.5 mg
15 mL tid.
Child: Each bottle contains carbocisteine 100 mg and promethazine hydrochloride 2.5 mg
<2 years Not recommended. 2-5 years 2.5-5 mL four times a day. 6-12 years 7.5-12.5 mL tid. 12-15 years 12.5-15 mL tid.
Active peptic ulcer. Children <2 years.
Special Precautions
Patient with epilepsy, signs and symptoms suggestive of Reye’s syndrome. Children >2 years. Pregnancy and lactation.
Adverse Reactions
Significant: Anticholinergic effects (e.g. blurred vision, dry mouth, urinary retention). Drowsiness, dizziness, restlessness, headache, nightmare, tiredness, disorientation, photosensitivity.
Gastrointestinal disorders: Nausea, gastric discomfort, GI bleeding, diarrhoea.
Skin and subcutaneous tissue disorders: Rarely, rash, urticaria, pruritus.
Potentially Fatal: Respiratory depression and apnoea especially in children.
Patient Counseling Information
Avoid prolonged exposure to sunlight.
Monitor mental status, and CNS effects (e.g. sedation).
Drug Interactions
May potentiate the effects of antihypertensive agents, other CNS depressants, MAOI(s) and analgesics.
Food Interaction
May enhance the CNS depressant effect of alcohol.
Lab Interference
Promethazine: May interfere with immunological urine pregnancy test to produce false-positive or false-negative results. Increased serum glucose may be seen with glucose tolerance tests. May lead to a false-positive result with urine detection of amphetamine/methamphetamine. May alter the flare response in intradermal allergen tests.
Description: Carbocisteine is a mucolytic agent that reduces goblet cell hyperplasia in the management of respiratory disorders associated with abnormally excessive or viscous mucus secretion.
Promethazine is a phenothiazine derivative which blocks postsynaptic mesolimbic dopaminergic receptors in the brain. It exhibits a strong α-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones. It competes with histamine for the H1-receptor; muscarinic blocking effect may be responsible for antiemetic activity. It also reduces stimuli to the brainstem reticular system.
Onset: Promethazine: Approx 20 minutes.
Absorption: Carbocisteine: Rapidly and well absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 2 hours.
Promethazine: Rapidly and well absorbed. Bioavailabilty: Approx 25%. Time to peak plasma concentration: 2-3 hours.
Distribution: Carbocisteine: Penetrates into lung tissue and respiratory mucus.
Promethazine: Crosses the blood-brain barrier and placenta; enters breast (small amounts). Volume of distribution: 13.3 ± 3.6 L/kg. Plasma protein binding: 76-93%.
Metabolism: Carbocisteine: Metabolised via acetylation, decarboxylation, and sulfoxidation by genetic polymorphism.
Undergoes extensive hepatic-first pass metabolism via hydroxylation by CYP2D6 and N-demethylation by CYB2B6.
Excretion: Carbocisteine: Via urine, as unchanged drug and metabolites.
Promethazine: Via urine; faeces, as metabolites. Elimination half-life: Approx 5-14 hours.
Chemical Structure

Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Store between 20-25°C. Protect from light.
Disclaimer: This information is independently developed by MIMS based on Carbocisteine + Promethazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
  • CP Cough Syrup
  • Mucoprom
  • Zoradine-Pro
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in